sarepta gene therapy - Search News

News

Gene Therapy, Patient and Sarepta

What’s next for Sarepta Therapeutics with gene therapy under fire?

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also undermining investor confidence in the company that makes it.

Barron's on MSN · 3d

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug’s outlook.

Boston Herald · 2d

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio cream

STAT2h

FDA’s gene therapy turmoil, and an alternative model for funding research

We look at the continued turmoil within the FDA, including the forced dismissal of top gene therapy regulator Nicole Verdun, as well as the announcement of a controversial drug-review voucher program ...

BioSpace1d

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Why Sarepta Therapeutics (SRPT) Stock Is Down Today

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a ...

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results